Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lamivudine

FDA-approved product (tablet, oral), marketed as Epivir, Epivir-Hbv, Lamivudine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lamivudine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Inflammation
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF05; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lamivudine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lamivudine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lamivudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

    NCT06967753 · start 2025-07-31

    Registered record
    Registry ID
    NCT06967753
    Conditions
    HIV; HIV-1
    Interventions
    Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-31
    Completion
    2027-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV-1
    InterventionDolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
    PhasePhase 4
    Registry statusRecruiting

  • Transgender Men and HIV in Uganda: PrEP Uptake and Persistence

    NCT04867798 · start 2021-09-16

    Registered record
    Registry ID
    NCT04867798
    Conditions
    HIV; Sexually Transmitted Infections; PrEP; Transgender Men
    Interventions
    Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-09-16
    Completion
    2023-04-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Sexually Transmitted Infections; PrEP; Transgender Men
    InterventionLamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet
    PhaseNot recorded
    Registry statusCompleted

  • Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

    NCT04296695 · start 2021-07-14

    Registered record
    Registry ID
    NCT04296695
    Conditions
    HIV-1-infection
    Interventions
    B/F/TAF; TDF/3TC/EFV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-07-14
    Completion
    2025-06-06
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionB/F/TAF; TDF/3TC/EFV
    PhasePhase 4
    Registry statusCompleted

  • Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

    NCT04375800 · start 2021-02-03

    Registered record
    Registry ID
    NCT04375800
    Conditions
    Human Immunodeficiency Virus (HIV) Infection
    Interventions
    Doravirine; 2 NRTIs; DOR/3TC/TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-02-03
    Completion
    2034-04-11
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV) Infection
    InterventionDoravirine; 2 NRTIs; DOR/3TC/TDF
    PhasePhase 2
    Registry statusRecruiting

  • REal-Life Cohort With DOlutegravir + LAmivudina

    NCT04638686 · start 2020-06-15

    Registered record
    Registry ID
    NCT04638686
    Conditions
    HIV-1-infection
    Interventions
    Dolutegravir 50 MG; Lamivudine 300 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-06-15
    Completion
    2022-03-31
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDolutegravir 50 MG; Lamivudine 300 MG
    PhaseNot recorded
    Registry statusCompleted

  • Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV

    NCT03869944 · start 2019-12-04

    Registered record
    Registry ID
    NCT03869944
    Conditions
    HIV-1
    Interventions
    Lamivudine Oral Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-12-04
    Completion
    2022-03
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionLamivudine Oral Solution
    PhasePhase 2
    Registry statusUnknown

  • 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

    NCT04019873 · start 2019-11-18

    Registered record
    Registry ID
    NCT04019873
    Conditions
    HIV Infections
    Interventions
    Dolutegravir (DTG); Lamivudine (3TC); Rilpivirine (RPV)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-11-18
    Completion
    2023-12-05
    Enrolment
    774

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDolutegravir (DTG); Lamivudine (3TC); Rilpivirine (RPV)
    PhaseNot recorded
    Registry statusCompleted

  • Optimization of Antiretroviral Therapy

    NCT02935075 · start 2018-03-05

    Registered record
    Registry ID
    NCT02935075
    Conditions
    HIV Infections
    Interventions
    Tenofovir disoproxil fumarate; Lamivudine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-05
    Completion
    2019-08-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTenofovir disoproxil fumarate; Lamivudine; Efavirenz
    PhasePhase 4
    Registry statusCompleted

  • Gut Microbiota and Immune Recovery

    NCT03478540 · start 2017-12-01

    Registered record
    Registry ID
    NCT03478540
    Conditions
    HIV-1-infection
    Interventions
    Anti-Retroviral Agents
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-12-01
    Completion
    2019-05-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionAnti-Retroviral Agents
    PhaseNot recorded
    Registry statusUnknown

  • Carvedilol for Prevention of Esophageal Varices Progression

    NCT03736265 · start 2017-10-09

    Registered record
    Registry ID
    NCT03736265
    Conditions
    Cirrhosis, Liver; Portal Hypertension
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-10-09
    Completion
    2022-12-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Portal Hypertension
    InterventionCarvedilol
    PhaseNot applicable
    Registry statusUnknown

  • Nevirapine + 3TC Based Maintenance Therapy for HIV Infection

    NCT03223402 · start 2016-12-23

    Registered record
    Registry ID
    NCT03223402
    Conditions
    HIV Infections
    Interventions
    Nevirapine plus lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-12-23
    Completion
    2018-05-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine plus lamivudine
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

    NCT02777229 · start 2016-07

    Registered record
    Registry ID
    NCT02777229
    Conditions
    HIV-1 Infection
    Interventions
    Dolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07
    Completion
    2021-07
    Enrolment
    616

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    PhasePhase 3
    Registry statusCompleted

  • Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

    NCT02738931 · start 2016-05

    Registered record
    Registry ID
    NCT02738931
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    Dolutegravir 50 mg tablet; Lamivudine 300 mg tablet; Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA); Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05
    Completion
    2016-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionDolutegravir 50 mg tablet; Lamivudine 300 mg tablet; Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA); Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

    NCT02596334 · start 2015-12-23

    Registered record
    Registry ID
    NCT02596334
    Conditions
    HIV
    Interventions
    dolutegravir 50mg +abacavir 600mg +lamivudine 300mg; dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-12-23
    Completion
    2018-06-23
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiondolutegravir 50mg +abacavir 600mg +lamivudine 300mg; dolutegravir
    PhasePhase 3
    Registry statusTerminated

  • The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

    NCT02581202 · start 2015-12-21

    Registered record
    Registry ID
    NCT02581202
    Conditions
    HIV-1 Infection
    Interventions
    lopinavir/ritonavir; lamivudine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-12-21
    Completion
    2017-05-27
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventionlopinavir/ritonavir; lamivudine
    PhaseNot recorded
    Registry statusCompleted